Sterling Investment Advisors (Pennsylvania)’s Sarepta Therapeutics SRPT Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300	Closed	-$22K	–	461
2022 Q2	$22K	Hold	300	–	–	0.01%	322
2022 Q1	$23K	Hold	300	–	–	0.01%	345
2021 Q4	$27K	Hold	300	–	–	0.01%	334
2021 Q3	$28K	Hold	300	–	–	0.01%	324
2021 Q2	$23K	Hold	300	–	–	0.01%	342
2021 Q1	$22K	Hold	300	–	–	0.01%	327
2020 Q4	$51K	Hold	300	–	–	0.02%	223
2020 Q3	$42K	Hold	300	–	–	0.02%	228
2020 Q2	$48K	Hold	300	–	–	0.02%	215
2020 Q1	$29K	Hold	300	–	–	0.02%	239
2019 Q4	$38K	Hold	300	–	–	0.02%	234
2019 Q3	$23K	Hold	300	–	–	0.01%	277
2019 Q2	$46K	Sell	300 -200	-40%	-$24.3K	0.02%	215
2019 Q1	$60K	Hold	500	–	–	0.03%	193
2018 Q4	$54K	Hold	500	–	–	0.03%	189
2018 Q3	$81K	Buy	+500	New	+$68.4K	0.04%	175

Other funds holding SRPT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s SRPT Position: Q3 2022 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Sarepta Therapeutics (SRPT) in Q3 2022, closing a stake of 300 shares — an estimated $22K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in SRPT in Q3 2018 and held it in 16 quarters. The position peaked at $81K in Q3 2018. 376 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.

Sterling Investment Advisors (Pennsylvania) reported no remaining Sarepta Therapeutics position as of Q3 2022 after selling out during the quarter.
Sterling Investment Advisors (Pennsylvania) sold 300 Sarepta Therapeutics shares in Q3 2022, an estimated $22K.
Sterling Investment Advisors (Pennsylvania) first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 16 quarters.
Sterling Investment Advisors (Pennsylvania)'s Sarepta Therapeutics position peaked at $81K in Q3 2018.
376 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2022, filed 3 Nov 2022.